$CCEL
CRYO CELL INTERNATIONAL INC

2022 Q3 Form 10-Q Financial Statement

#000095017022012605 Filed on July 11, 2022

View on sec.gov

Income Statement

Concept 2022 Q3 2022 Q2 2022 Q1
Revenue $7.681M $7.633M $7.259M
YoY Change 2.36% 5.94% 5.8%
Cost Of Revenue $2.349M $2.202M $2.103M
YoY Change -4.48% -0.95% 4.52%
Gross Profit $5.332M $5.432M $5.155M
YoY Change 5.7% 9.01% 6.33%
Gross Profit Margin 69.42% 71.16% 71.02%
Selling, General & Admin $3.603M $3.913M $3.376M
YoY Change 3.14% 24.27% -1.67%
% of Gross Profit 67.58% 72.03% 65.48%
Research & Development $80.27K $80.90K $147.2K
YoY Change 702.72% 2399.1% 2278.35%
% of Gross Profit 1.51% 1.49% 2.86%
Depreciation & Amortization $369.0K $364.7K $396.1K
YoY Change 15.08% 14.41% 446.44%
% of Gross Profit 6.92% 6.71% 7.68%
Operating Expenses $3.684M $3.993M $3.523M
YoY Change 6.82% 26.71% 2.43%
Operating Profit $954.3K $1.194M $1.470M
YoY Change -40.22% -40.13% 19.04%
Interest Expense $365.3K $276.5K $306.1K
YoY Change 8.78% -19.0% 9.23%
% of Operating Profit 38.28% 23.15% 20.82%
Other Income/Expense, Net -$313.3K -$294.6K -$314.7K
YoY Change -1044583.33% -16.75% 11.3%
Pretax Income $641.0K $899.8K $1.156M
YoY Change -49.18% -45.18% 21.33%
Income Tax $174.1K $265.1K $323.6K
% Of Pretax Income 27.17% 29.46% 28.0%
Net Earnings $466.8K $634.7K $832.0K
YoY Change -45.5% -45.78% 19.96%
Net Earnings / Revenue 6.08% 8.32% 11.46%
Basic Earnings Per Share $0.06 $0.08 $0.10
Diluted Earnings Per Share $0.06 $0.07 $0.10
COMMON SHARES
Basic Shares Outstanding 8.388M 8.438M 8.527M
Diluted Shares Outstanding 8.404M 8.553M 8.748M

Balance Sheet

Concept 2022 Q3 2022 Q2 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $2.963M $2.868M $2.617M
YoY Change -61.89% -64.25% -76.97%
Cash & Equivalents $2.925M $2.804M $2.145M
Short-Term Investments $38.70K $63.13K $472.4K
Other Short-Term Assets $1.267M $844.8K $483.5K
YoY Change 46.84% 28.79% -41.42%
Inventory $919.3K $873.2K $927.6K
Prepaid Expenses $644.8K $569.6K $537.7K
Receivables $5.347M $5.150M $5.152M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $11.14M $10.31M $9.717M
YoY Change -25.33% -30.29% -48.03%
LONG-TERM ASSETS
Property, Plant & Equipment $15.18M $4.028M $3.805M
YoY Change 277.52% 53.7% 45.79%
Goodwill $1.941M $1.941M $1.941M
YoY Change
Intangibles $1.487M $1.512M $1.536M
YoY Change
Long-Term Investments $308.0K $308.0K $308.0K
YoY Change 0.0% 0.0% 0.0%
Other Assets $40.45M $41.06M $41.29M
YoY Change 10.33% -2.19% -48.49%
Total Long-Term Assets $55.62M $45.09M $45.09M
YoY Change 24.99% 3.57% -47.91%
TOTAL ASSETS
Total Short-Term Assets $11.14M $10.31M $9.717M
Total Long-Term Assets $55.62M $45.09M $45.09M
Total Assets $66.77M $55.39M $54.81M
YoY Change 12.35% -5.01% -47.93%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.793M $1.723M $1.848M
YoY Change 79.42% 39.34% 114.82%
Accrued Expenses $2.185M $2.075M $2.104M
YoY Change 11.84% 39.15% -43.08%
Deferred Revenue $9.546M $9.292M $9.057M
YoY Change 2.36% 2.09%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $154.3K $357.8K $1.129M
YoY Change -94.21% -88.46% -63.57%
Total Short-Term Liabilities $23.62M $15.71M $16.39M
YoY Change 18.96% -21.91% -45.09%
LONG-TERM LIABILITIES
Long-Term Debt $8.609M $0.00 $0.00
YoY Change -100.0% -100.0%
Other Long-Term Liabilities $45.53M $35.28M $34.17M
YoY Change 30.95% 4.15% -55.06%
Total Long-Term Liabilities $45.53M $35.28M $34.17M
YoY Change 30.95% 3.16% -55.69%
TOTAL LIABILITIES
Total Short-Term Liabilities $23.62M $15.71M $16.39M
Total Long-Term Liabilities $45.53M $35.28M $34.17M
Total Liabilities $69.15M $50.99M $50.56M
YoY Change 26.59% -6.13% -52.73%
SHAREHOLDERS EQUITY
Retained Earnings -$22.48M -$15.27M -$15.90M
YoY Change -9.94%
Common Stock $42.59M $41.91M $41.80M
YoY Change 0.95%
Preferred Stock
YoY Change
Treasury Stock (at cost) $22.51M $22.24M $21.64M
YoY Change 8.14%
Treasury Stock Shares $6.323M $6.276M $6.190M
Shareholders Equity -$2.386M $4.407M $4.251M
YoY Change
Total Liabilities & Shareholders Equity $66.77M $55.39M $54.81M
YoY Change 12.35% -5.01% -47.93%

Cashflow Statement

Concept 2022 Q3 2022 Q2 2022 Q1
OPERATING ACTIVITIES
Net Income $466.8K $634.7K $832.0K
YoY Change -45.5% -45.78% 19.96%
Depreciation, Depletion And Amortization $369.0K $364.7K $396.1K
YoY Change 15.08% 14.41% 446.44%
Cash From Operating Activities $2.689M $1.947M $1.507M
YoY Change 30.56% 26.68% -43.4%
INVESTING ACTIVITIES
Capital Expenditures -$11.24M -$307.0K $647.6K
YoY Change 633.74% 2883.19% 5306.89%
Acquisitions
YoY Change
Other Investing Activities $12.80K $391.1K -$5.406M
YoY Change -107.89% 3503.73%
Cash From Investing Activities -$11.23M $84.09K -$6.053M
YoY Change 632.9% -101.69% 3637.07%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $829.0K
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 8.657M -1.371M -1.572M
YoY Change -1217.08% -1476.02% -0.72%
NET CHANGE
Cash From Operating Activities 2.689M 1.947M 1.507M
Cash From Investing Activities -11.23M 84.09K -6.053M
Cash From Financing Activities 8.657M -1.371M -1.572M
Net Change In Cash 120.2K 659.8K -6.118M
YoY Change -148.63% -119.82% -767.45%
FREE CASH FLOW
Cash From Operating Activities $2.689M $1.947M $1.507M
Capital Expenditures -$11.24M -$307.0K $647.6K
Free Cash Flow $13.93M $2.254M $859.1K
YoY Change 287.83% 45.68% -67.58%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--11-30
ccel Liabilities Incurred For The Purchase Of Patents And Licenses
LiabilitiesIncurredForThePurchaseOfPatentsAndLicenses
ccel Patent Option Agreement Credit To Purchase Of Patents And Licenses
PatentOptionAgreementCreditToPurchaseOfPatentsAndLicenses
dei Entity Address Address Line1
EntityAddressAddressLine1
700 Brooker Creek Blvd
dei Entity Address City Or Town
EntityAddressCityOrTown
Oldsmar
dei Entity Address State Or Province
EntityAddressStateOrProvince
FL
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
34677
dei City Area Code
CityAreaCode
813
dei Local Phone Number
LocalPhoneNumber
749-2100
dei Security12b Title
Security12bTitle
Common Stock, $0.01 par value
dei Trading Symbol
TradingSymbol
CCEL
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
ccel Lease Liability Arising From Right Of Use Asset
LeaseLiabilityArisingFromRightOfUseAsset
dei Amendment Flag
AmendmentFlag
false
dei Entity Central Index Key
EntityCentralIndexKey
0000862692
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-05-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-40767
dei Entity Registrant Name
EntityRegistrantName
CRYO-CELL INTERNATIONAL, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
22-3023093
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
8388290
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2804452
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
8263088
CY2022Q2 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
63125
CY2021Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
75412
CY2022Q2 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
3233575
CY2021Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
3078439
CY2022Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
5150154
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
5253173
CY2022Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
569630
CY2021Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
558413
CY2022Q2 us-gaap Inventory Net
InventoryNet
873157
CY2021Q4 us-gaap Inventory Net
InventoryNet
921213
CY2022Q2 us-gaap Other Assets Current
OtherAssetsCurrent
844774
CY2021Q4 us-gaap Other Assets Current
OtherAssetsCurrent
711208
CY2022Q2 us-gaap Assets Current
AssetsCurrent
10305292
CY2021Q4 us-gaap Assets Current
AssetsCurrent
15782507
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4027969
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3230204
ccel Payment Of Duke License Agreement
PaymentOfDukeLicenseAgreement
5000000
CY2022Q2 ccel Duke License Agreement
DukeLicenseAgreement
14171415
CY2021Q4 ccel Duke License Agreement
DukeLicenseAgreement
14651802
CY2022Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
1511502
CY2021Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
1559693
CY2022Q2 us-gaap Inventory Noncurrent
InventoryNoncurrent
9552616
CY2021Q4 us-gaap Inventory Noncurrent
InventoryNoncurrent
9695363
CY2022Q2 us-gaap Goodwill
Goodwill
1941411
CY2021Q4 us-gaap Goodwill
Goodwill
1941411
CY2022Q2 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
12010133
CY2021Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
12010133
CY2022Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
762617
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
916493
CY2022Q2 ccel Deposits And Other Assets
DepositsAndOtherAssets
803991
CY2021Q4 ccel Deposits And Other Assets
DepositsAndOtherAssets
566470
CY2022Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
41061685
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
41649365
CY2022Q2 us-gaap Assets
Assets
55394946
CY2021Q4 us-gaap Assets
Assets
60662076
CY2022Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
1722552
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1489774
CY2022Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2074987
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3057386
CY2022Q2 us-gaap Notes Payable Current
NotesPayableCurrent
357842
CY2021Q4 us-gaap Notes Payable Current
NotesPayableCurrent
1898065
CY2022Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
315042
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
312067
CY2022Q2 ccel Duke License Agreement Liability Current
DukeLicenseAgreementLiabilityCurrent
1949539
CY2021Q4 ccel Duke License Agreement Liability Current
DukeLicenseAgreementLiabilityCurrent
4957591
CY2022Q2 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
9291530
CY2021Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
9358696
CY2022Q2 us-gaap Liabilities Current
LiabilitiesCurrent
15711492
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
21073579
CY2022Q2 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
33372659
CY2021Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
31274214
CY2022Q2 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
574833
CY2021Q4 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
727371
CY2022Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
453979
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
610989
CY2022Q2 us-gaap Other Long Term Debt Noncurrent
OtherLongTermDebtNoncurrent
875000
CY2021Q4 us-gaap Other Long Term Debt Noncurrent
OtherLongTermDebtNoncurrent
875000
CY2022Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
35276471
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
35404183
CY2022Q2 us-gaap Liabilities
Liabilities
50987963
CY2021Q4 us-gaap Liabilities
Liabilities
56477762
CY2022Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
0
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
0
CY2022Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2022Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
500000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
500000
CY2022Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q2 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
20000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
20000000
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
14675772
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
8399490
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
14665772
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
8551816
CY2022Q2 us-gaap Common Stock Value
CommonStockValue
146758
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
146658
CY2022Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
41767841
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
41586583
CY2022Q2 us-gaap Treasury Stock Value
TreasuryStockValue
22238189
CY2021Q4 us-gaap Treasury Stock Value
TreasuryStockValue
20812734
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-15269427
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-16736193
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
4406983
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
4184314
CY2022Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
55394946
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
60662076
CY2022Q2 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
7633217
CY2021Q2 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
7205195
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
14891748
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
14065812
CY2022Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
2201540
CY2021Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
2222671
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
4304742
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
4234868
CY2022Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
3912586
CY2021Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
3148396
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
7288540
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
6581708
CY2022Q2 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
36105
CY2021Q2 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-431599
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-152538
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-279205
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
80896
CY2021Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3237
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
228116
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9427
CY2022Q2 us-gaap Depreciation And Amortization
DepreciationAndAmortization
279926
CY2021Q2 us-gaap Depreciation And Amortization
DepreciationAndAmortization
267422
us-gaap Depreciation And Amortization
DepreciationAndAmortization
558092
us-gaap Depreciation And Amortization
DepreciationAndAmortization
288685
CY2022Q2 us-gaap Costs And Expenses
CostsAndExpenses
6438843
CY2021Q2 us-gaap Costs And Expenses
CostsAndExpenses
5210127
us-gaap Costs And Expenses
CostsAndExpenses
12226952
us-gaap Costs And Expenses
CostsAndExpenses
10835483
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
1194374
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
1995068
us-gaap Operating Income Loss
OperatingIncomeLoss
2664796
us-gaap Operating Income Loss
OperatingIncomeLoss
3230329
CY2022Q2 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-18188
CY2021Q2 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-12512
us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-26830
us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-15088
CY2022Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
118
CY2021Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
25
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
127
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
50
CY2022Q2 us-gaap Interest Expense
InterestExpense
276524
CY2021Q2 us-gaap Interest Expense
InterestExpense
341390
us-gaap Interest Expense
InterestExpense
582619
us-gaap Interest Expense
InterestExpense
621609
CY2022Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-294594
CY2021Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-353877
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-609322
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-636647
CY2022Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
899780
CY2021Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
1641191
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
2055474
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
2593682
CY2022Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
265061
CY2021Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
470562
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
588708
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
729463
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
634719
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
1170629
us-gaap Net Income Loss
NetIncomeLoss
1466766
us-gaap Net Income Loss
NetIncomeLoss
1864219
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.08
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.15
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.17
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.24
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8437544
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7950791
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8479071
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7760214
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.07
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.14
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.17
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.23
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8553085
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8273767
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8643106
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8060506
us-gaap Profit Loss
ProfitLoss
1466766
us-gaap Profit Loss
ProfitLoss
1864219
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
760759
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
391218
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-152538
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-279205
us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-26830
us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-15088
us-gaap Share Based Compensation
ShareBasedCompensation
149358
us-gaap Share Based Compensation
ShareBasedCompensation
152572
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
399953
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
105279
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
9777
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
35072
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
153876
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
136116
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
296934
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-1002125
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
11217
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-261691
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-190803
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-108414
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
133566
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
61299
ccel Increase Decrease In Deposits And Other Assets
IncreaseDecreaseInDepositsAndOtherAssets
237521
ccel Increase Decrease In Deposits And Other Assets
IncreaseDecreaseInDepositsAndOtherAssets
113564
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
232778
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
278800
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-982399
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1407076
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-154035
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-133259
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
2031279
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
1842959
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
3453969
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
4199150
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
954607
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
22272
ccel Payment Of Duke License Agreement
PaymentOfDukeLicenseAgreement
5106224
ccel Payments To Acquire Marketable Securities And Other Investments
PaymentsToAcquireMarketableSecuritiesAndOtherInvestments
1142212
ccel Payments To Acquire Marketable Securities And Other Investments
PaymentsToAcquireMarketableSecuritiesAndOtherInvestments
0
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
1127669
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
-0
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-5969150
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-5128496
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
1425455
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
0
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
1550000
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
2550000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
32000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1066290
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-2943455
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-1483710
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-5458636
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-2413056
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
8263088
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
10361125
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
2804452
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
7948069
ccel Lease Liability Arising From Right Of Use Asset
LeaseLiabilityArisingFromRightOfUseAsset
904691
ccel Patent Option Agreement Credit To Purchase Of Patents And Licenses
PatentOptionAgreementCreditToPurchaseOfPatentsAndLicenses
500000
ccel Liabilities Incurred For The Purchase Of Patents And Licenses
LiabilitiesIncurredForThePurchaseOfPatentsAndLicenses
11258083
us-gaap Stock Issued1
StockIssued1
0
us-gaap Stock Issued1
StockIssued1
3585172
us-gaap Interest Paid Net
InterestPaidNet
483641
us-gaap Interest Paid Net
InterestPaidNet
516000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
756133
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
1901025
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
4251277
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
117462
CY2022Q2 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
596475
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
634719
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
4406983
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
4184314
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
32000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
149358
us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
1425455
us-gaap Net Income Loss
NetIncomeLoss
1466766
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
4406983
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
-1695105
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
4459840
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
67754
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
1170629
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
4003118
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-2665135
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
4651462
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
152572
us-gaap Net Income Loss
NetIncomeLoss
1864219
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
4003118
CY2022Q2 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
42664189
CY2022Q2 ccel Revenue Remaining Performance Obligation Next Twelve Months
RevenueRemainingPerformanceObligationNextTwelveMonths
9291530
CY2022Q2 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
P12M
CY2005Q4 us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
50000
CY2005Q4 us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
50000
CY2012Q1 us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
75000
CY2017Q2 us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
100000
CY2022Q2 us-gaap Sales Commissions And Fees
SalesCommissionsAndFees
12169
us-gaap Sales Commissions And Fees
SalesCommissionsAndFees
27321
CY2021Q2 us-gaap Sales Commissions And Fees
SalesCommissionsAndFees
8198
us-gaap Sales Commissions And Fees
SalesCommissionsAndFees
21705
CY2022Q2 ccel Increase Decrease In Capitalized Contract Cost
IncreaseDecreaseInCapitalizedContractCost
27170
ccel Increase Decrease In Capitalized Contract Cost
IncreaseDecreaseInCapitalizedContractCost
51759
CY2021Q2 ccel Increase Decrease In Capitalized Contract Cost
IncreaseDecreaseInCapitalizedContractCost
27672
ccel Increase Decrease In Capitalized Contract Cost
IncreaseDecreaseInCapitalizedContractCost
45934
CY2022Q2 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
573043
CY2021Q4 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
535522
CY2022Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
5150154
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
5253173
CY2022Q2 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
9291530
CY2021Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
9358696
CY2022Q2 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
33372659
CY2021Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
31274214
CY2022Q2 ccel Impairment Of Contract Assets
ImpairmentOfContractAssets
0
ccel Impairment Of Contract Assets
ImpairmentOfContractAssets
0
CY2021Q4 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
535522
ccel Contract With Customer Asset Net Current Additions
ContractWithCustomerAssetNetCurrentAdditions
51759
ccel Contract With Customer Asset Net Current Deductions
ContractWithCustomerAssetNetCurrentDeductions
14238
CY2022Q2 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
573043
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
5253173
ccel Accounts Receivable Net Current Additions
AccountsReceivableNetCurrentAdditions
18402414
ccel Accounts Receivable Net Current Deductions
AccountsReceivableNetCurrentDeductions
18505433
CY2022Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
5150154
CY2021Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
40632910
ccel Contract With Customer Liability Additions
ContractWithCustomerLiabilityAdditions
11840456
ccel Contract With Customer Liability Deductions
ContractWithCustomerLiabilityDeductions
9809177
CY2022Q2 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
42664189
CY2020Q4 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
466141
ccel Contract With Customer Asset Net Current Additions
ContractWithCustomerAssetNetCurrentAdditions
45934
ccel Contract With Customer Asset Net Current Deductions
ContractWithCustomerAssetNetCurrentDeductions
12447
CY2021Q2 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
499628
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
6322960
ccel Accounts Receivable Net Current Additions
AccountsReceivableNetCurrentAdditions
18178409
ccel Accounts Receivable Net Current Deductions
AccountsReceivableNetCurrentDeductions
19285813
CY2021Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
5215556
CY2020Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
36384360
ccel Contract With Customer Liability Additions
ContractWithCustomerLiabilityAdditions
8430850
ccel Contract With Customer Liability Deductions
ContractWithCustomerLiabilityDeductions
6587891
CY2021Q2 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
38227319
CY2021Q4 us-gaap Other Asset Impairment Charges
OtherAssetImpairmentCharges
1164499
CY2022Q2 us-gaap Liability For Uncertain Tax Positions Current
LiabilityForUncertainTaxPositionsCurrent
0
us-gaap Tax Adjustments Settlements And Unusual Provisions
TaxAdjustmentsSettlementsAndUnusualProvisions
0
us-gaap Tax Adjustments Settlements And Unusual Provisions
TaxAdjustmentsSettlementsAndUnusualProvisions
0
CY2022Q2 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2021Q2 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2022Q2 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
149000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
153000
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
117000
CY2021Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
68000
CY2022Q2 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
1500000
CY2021Q2 us-gaap Marketable Securities Gain Loss
MarketableSecuritiesGainLoss
13000
us-gaap Marketable Securities Gain Loss
MarketableSecuritiesGainLoss
15000
CY2022Q2 us-gaap Marketable Securities Gain Loss
MarketableSecuritiesGainLoss
18000
us-gaap Marketable Securities Gain Loss
MarketableSecuritiesGainLoss
27000
us-gaap Guarantees Indemnifications And Warranties Policies
GuaranteesIndemnificationsAndWarrantiesPolicies
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Product Warranty and Cryo-Cell Cares</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">TM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> Program</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">In December 2005, the Company began providing its customers that enrolled after December 2005 a payment warranty under which the Company agrees to pay $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">50,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> to its client if the umbilical cord blood product retrieved is used for a stem cell transplant for the donor or an immediate family member and fails to engraft, subject to various restrictions. Effective February 1, 2012, the Company increased the $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">50,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> payment warranty to a $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">75,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> payment warranty to all of its new clients. Effective June 1, 2017, the Company increased the payment warranty to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">100,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> to all new clients who choose the premium processing method, PrepaCyte CB. The product warranty is available to clients who enroll under this structure for as long as the specimen is stored with the Company. The Company has not experienced any claims under the warranty program nor has it incurred costs related to these warranties.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span> </p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">As discussed above, the Company has determined that the payment warranty represents variable consideration payable to the customer. In accordance with ASC 606, the Company has concluded the payment warranty be fully constrained under the most likely amount method; therefore, the transaction price does not reflect any expectation of service level credits at May 31, 2022 and November 30, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">. At the end of each reporting period, the Company shall update the estimated transaction price related to the payment guarantee including updating its assessment of whether an estimate of variable consideration is constrained to represent faithfully the circumstances present at the end of the reporting period and the changes in circumstances during the reporting period.</span></p>
CY2005Q4 ccel Payment Warranty
PaymentWarranty
50000
CY2005Q4 ccel Payment Warranty
PaymentWarranty
50000
CY2012Q1 ccel Increased Payment Warranty
IncreasedPaymentWarranty
75000
CY2017Q2 ccel Increased Payment Warranty
IncreasedPaymentWarranty
100000
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
3
CY2022Q2 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
7633217
CY2021Q2 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
7205195
CY2022Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
2201540
CY2021Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
2222671
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
1194374
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
1995068
CY2022Q2 us-gaap Interest Expense
InterestExpense
276524
CY2021Q2 us-gaap Interest Expense
InterestExpense
341390
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
14891748
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
14065812
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
4304742
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
4234868
us-gaap Operating Income Loss
OperatingIncomeLoss
2664796
us-gaap Operating Income Loss
OperatingIncomeLoss
3230329
us-gaap Interest Expense
InterestExpense
582619
us-gaap Interest Expense
InterestExpense
621609
CY2022Q2 us-gaap Assets
Assets
55394946
CY2021Q4 us-gaap Assets
Assets
60662076
CY2021Q4 us-gaap Other Asset Impairment Charges
OtherAssetImpairmentCharges
1164499
us-gaap Interest Expense Debt
InterestExpenseDebt
18115
CY2022Q2 ccel Inventory Collection Kits
InventoryCollectionKits
29438
CY2021Q4 ccel Inventory Collection Kits
InventoryCollectionKits
42998
CY2022Q2 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
7718
CY2021Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
7718
ccel Amortization Of Debt Issuance Costs
AmortizationOfDebtIssuanceCosts
35072
CY2022Q2 ccel Inventory Current And Noncurrent
InventoryCurrentAndNoncurrent
10425773
CY2021Q4 ccel Inventory Current And Noncurrent
InventoryCurrentAndNoncurrent
10616576
CY2022Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
1511502
CY2021Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
1559693
CY2022Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
24000
CY2021Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
24000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
48000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
41000
CY2022Q2 us-gaap Deferred Finance Costs Noncurrent Gross
DeferredFinanceCostsNoncurrentGross
548085
CY2022Q2 ccel Amortization Of Debt Issuance Costs
AmortizationOfDebtIssuanceCosts
3388
ccel Amortization Of Debt Issuance Costs
AmortizationOfDebtIssuanceCosts
9777
CY2021Q2 ccel Amortization Of Debt Issuance Costs
AmortizationOfDebtIssuanceCosts
15390
CY2022Q2 us-gaap Notes Payable
NotesPayable
358433
CY2021Q4 us-gaap Notes Payable
NotesPayable
1908433
CY2022Q2 us-gaap Unamortized Debt Issuance Expense
UnamortizedDebtIssuanceExpense
591
CY2021Q4 us-gaap Unamortized Debt Issuance Expense
UnamortizedDebtIssuanceExpense
10368
CY2022Q2 us-gaap Long Term Debt
LongTermDebt
357842
CY2021Q4 us-gaap Long Term Debt
LongTermDebt
1898065
CY2022Q2 us-gaap Interest Expense Debt
InterestExpenseDebt
5969
CY2022Q2 ccel Amortization Of Debt Issuance Costs
AmortizationOfDebtIssuanceCosts
3388
ccel Amortization Of Debt Issuance Costs
AmortizationOfDebtIssuanceCosts
9777
CY2022Q2 us-gaap Interest Expense Long Term Debt
InterestExpenseLongTermDebt
9357
us-gaap Interest Expense Long Term Debt
InterestExpenseLongTermDebt
27892
CY2021Q2 us-gaap Interest Expense Debt
InterestExpenseDebt
32894
us-gaap Interest Expense Debt
InterestExpenseDebt
73432
CY2021Q2 ccel Amortization Of Debt Issuance Costs
AmortizationOfDebtIssuanceCosts
15390
ccel Amortization Of Debt Issuance Costs
AmortizationOfDebtIssuanceCosts
35072
CY2021Q2 us-gaap Interest Expense Long Term Debt
InterestExpenseLongTermDebt
48284
us-gaap Interest Expense Long Term Debt
InterestExpenseLongTermDebt
108504
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
634719
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
1170629
us-gaap Net Income Loss
NetIncomeLoss
1466766
us-gaap Net Income Loss
NetIncomeLoss
1864219
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8437544
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7950791
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8479071
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7760214
CY2022Q2 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
115541
CY2021Q2 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
322976
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
164035
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
300292
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8553085
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8273767
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8643106
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8060506
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.08
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.15
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.17
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.24
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.07
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.14
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.17
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.23
CY2022Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
288381
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
90100
CY2021Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
20000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
27000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
4.56
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue
7.98
CY2022Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
96914
CY2022Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
4.52
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
4.56
CY2022Q2 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
495943
us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
P4Y5M26D
CY2022Q2 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
6.54
CY2022Q2 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
399029
CY2022Q2 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
5.39
CY2021Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
63034
CY2021Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
4.99
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
52500
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
4.56
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
14204
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
5.67
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares
4416
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Plan Modification Description And Terms
ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms
The options were issued under the Company’s 2012 Stock Plan and vested 1/3 upon grant, 1/3 on December 1, 2020 and the remaining 1/3 on November 30, 2021.
CY2022Q1 us-gaap Contract With Customer Asset Purchase
ContractWithCustomerAssetPurchase
11200000
CY2022Q1 us-gaap Area Of Land
AreaOfLand
56000
CY2022Q1 ccel Initial Earnest Deposit Transferred
InitialEarnestDepositTransferred
200000
CY2022Q2 ccel Additional Deposit Transferred
AdditionalDepositTransferred
50000
CY2022Q2 ccel Expected Days To Complete Construction
ExpectedDaysToCompleteConstruction
P90D
CY2022Q2 us-gaap Real Estate Investment Property At Cost
RealEstateInvestmentPropertyAtCost
1850000
CY2022Q2 us-gaap Area Of Land
AreaOfLand
8800
CY2022Q2 us-gaap Escrow Deposit
EscrowDeposit
50000
CY2022Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
20000000
CY2011Q4 us-gaap Stock Repurchase Program Number Of Shares Authorized To Be Repurchased
StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
1000000
CY2012Q2 us-gaap Stock Repurchase Program Number Of Shares Authorized To Be Repurchased
StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
3000000
CY2015Q2 us-gaap Stock Repurchase Program Number Of Shares Authorized To Be Repurchased
StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
6000000
CY2016Q4 us-gaap Stock Repurchase Program Number Of Shares Authorized To Be Repurchased
StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
8000000
us-gaap Treasury Stock Acquired Repurchase Authorization
TreasuryStockAcquiredRepurchaseAuthorization
open market purchases, privately negotiated block trades, unsolicited negotiated transactions, and/or pursuant to any trading plan that may be adopted in accordance with Rule 10b5-1 of the Securities and Exchange Commission
CY2022Q2 us-gaap Treasury Stock Shares
TreasuryStockShares
6276282
CY2021Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
6113956
us-gaap Operating Lease Payments
OperatingLeasePayments
147130
CY2022Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
762617
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
916493
CY2022Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
315042
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
312067
CY2022Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
453979
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
610989
CY2022Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
769021
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
923056
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
170235
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
313996
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
295086
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
24591
CY2022Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
34887
CY2022Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
769021
CY2022Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y6M29D
CY2021Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y29D
CY2022Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.035
CY2021Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.035
CY2022Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
85964
CY2021Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
75564
us-gaap Operating Lease Payments
OperatingLeasePayments
171928
ccel Covid19
Covid19
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Note 12 – COVID-19</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">In March 2020, the World Health Organization declared a pandemic related to the rapidly spreading coronavirus (“COVID-19”) outbreak. The pandemic and government measures taken in response have had a significant adverse impact, both direct and indirect, on our business and the economy. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The Company faces various risks related to health epidemics, pandemics and similar outbreaks, including the global outbreak of COVID-19. The Company believes it has taken appropriate steps to minimize the risk to our employees and to maintain normal business operations and continues to actively monitor the global outbreak and spread of COVID-19 and continues to take steps to mitigate the potential risks to us posed by its spread and related circumstances and impacts. While the ultimate health and economic impact of COVID-19 remains highly uncertain, we expect that our business operations and results of operations, including our net sales, earnings and cash flows, may continue to be impacted by decreases in new client sales. We cannot predict the timing and speed of the recovery, and any delay in the recovery could significantly impact our future results.</span>
CY2020Q2 us-gaap Line Of Credit
LineOfCredit
350000
CY2020Q2 us-gaap Line Of Credit Facility Maximum Amount Outstanding During Period
LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod
150000
CY2020Q4 us-gaap Line Of Credit Facility Maximum Amount Outstanding During Period
LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod
150000

Files In Submission

Name View Source Status
0000950170-22-012605-index-headers.html Edgar Link pending
0000950170-22-012605-index.html Edgar Link pending
0000950170-22-012605.txt Edgar Link pending
0000950170-22-012605-xbrl.zip Edgar Link pending
ccel-20220531.htm Edgar Link pending
ccel-20220531.xsd Edgar Link pending
ccel-20220531_cal.xml Edgar Link unprocessable
ccel-20220531_def.xml Edgar Link unprocessable
ccel-20220531_htm.xml Edgar Link completed
ccel-20220531_lab.xml Edgar Link unprocessable
ccel-20220531_pre.xml Edgar Link unprocessable
ccel-ex31_1.htm Edgar Link pending
ccel-ex31_2.htm Edgar Link pending
ccel-ex31_3.htm Edgar Link pending
ccel-ex32_1.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending